Emma E. Recchia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Emma E. Recchia has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- David Kosoff
Department of Medicine University of Wisconsin‐Madison Madison Wisconsin USA
27 shared publications - Erika Heninger
University of Wisconsin–Madison 1 Madison, WI
27 shared publications - Shuang George Zhao
University of Wisconsin Department of Human Oncology, Madison, WI
26 shared publications - Aaron M. LeBeau
Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA
25 shared publications - Abigail E. Jackson
Department of Biochemistry, University of Utah, Salt Lake City, UT, USA
25 shared publications - Gihan S. Gunaratne
Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA
25 shared publications
Latest Publications
- Open Access
- 10 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 6 (6) , 1522-1530
Identifying and addressing barriers to live primary prostate cancer cell research in Veterans
Increased comorbidities and unique service-related exposures among Veterans may contribute to unique tumor biology that can influence tumor behavior and response to treatment. Research that incorporates live cells from Veteran donors can support investigation of the genomic and transcriptomic biology of Veteran tumors as well as how those molecular alterations impact tumor function, such as growth, metastasis and treatment sensitivity. We conducted a systematic literature review to assess Veteran-focused prostate cancer studies published in the last decade that incorporate live primary cells. We found that in the past 10 years, 105 prostate cancer studies were published that utilized live primary cells from the general population compared to zero studies utilizing live primary cells from Veterans. Analysis of Veterans enrolled in a study utilizing live primary cells at the William S Middleton VA demonstrated that 94% of Veterans who were presented with a live cell biospecimen donation study ultimately enrolled. Furthermore, survey responses from Veterans enrolled in this study showed that 83% of Veterans found their research engagement to be a meaningful experience and 70% reported increased healthcare satisfaction as a result of their participation. These findings suggest that the lack of live cell prostate cancer research in Veterans appears to be due to a lack of research opportunities for Veterans and not a lack of Veteran interest in participation Finally, we demonstrate that implementation of an informatics-based patient screening strategy can potentially support more Veteran-focused studies by reducing participant screening time by 89%.
- 10 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 6 (6) , 1522-1530
Open AccessIdentifying and addressing barriers to live primary prostate cancer cell research in Veterans
Increased comorbidities and unique service-related exposures among Veterans may contribute to unique tumor biology that can influence tumor behavior and response to treatment. Research that incorporates live cells from Veteran donors can support investigation of the genomic and transcriptomic biology of Veteran tumors as well as how those molecular alterations impact tumor function, such as growth, metastasis and treatment sensitivity. We conducted a systematic literature review to assess Veteran-focused prostate cancer studies published in the last decade that incorporate live primary cells. We found that in the past 10 years, 105 prostate cancer studies were published that utilized live primary cells from the general population compared to zero studies utilizing live primary cells from Veterans. Analysis of Veterans enrolled in a study utilizing live primary cells at the William S Middleton VA demonstrated that 94% of Veterans who were presented with a live cell biospecimen donation study ultimately enrolled. Furthermore, survey responses from Veterans enrolled in this study showed that 83% of Veterans found their research engagement to be a meaningful experience and 70% reported increased healthcare satisfaction as a result of their participation. These findings suggest that the lack of live cell prostate cancer research in Veterans appears to be due to a lack of research opportunities for Veterans and not a lack of Veteran interest in participation Finally, we demonstrate that implementation of an informatics-based patient screening strategy can potentially support more Veteran-focused studies by reducing participant screening time by 89%.
- Open Access
- 15 April 2026
- Published by Elsevier in SLAS Technology
- Vol. 38, 100421
Development of a novel fluid removal system to increase throughput and uniformity of fluid exchange in an open microfluidic culture platform
- 15 April 2026
- Published by Elsevier in SLAS Technology
- Vol. 38, 100421
Open AccessDevelopment of a novel fluid removal system to increase throughput and uniformity of fluid exchange in an open microfluidic culture platform
- Open Access
- 3 December 2024
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 224 (2)
One step 4× and 12× 3D-ExM enables robust super-resolution microscopy of nanoscale cellular structures
Super-resolution microscopy has become an indispensable tool across diverse research fields, offering unprecedented insights into biological architectures with nanometer scale resolution. Compared with traditional nanometer-scale imaging methods such as electron microscopy, super-resolution microscopy offers several advantages, including the simultaneous labeling of multiple target biomolecules with high specificity and simpler sample preparation, making it accessible to most researchers. In this study, we introduce two optimized methods of super-resolution imaging: 4-fold and 12-fold 3D-isotropic and preserved Expansion Microscopy (4× and 12× 3D-ExM). 3D-ExM is a straightforward expansion microscopy technique featuring a single-step process, providing robust and reproducible 3D isotropic expansion for both 2D and 3D cell culture models. With standard confocal microscopy, 12× 3D-ExM achieves a lateral resolution of <30 nm, enabling the visualization of nanoscale structures, including chromosomes, kinetochores, nuclear pore complexes, and Epstein–Barr virus particles. These results demonstrate that 3D-ExM provides cost-effective and user-friendly super-resolution microscopy, making it highly suitable for a wide range of cell biology research, including studies on cellular and chromatin architectures.
- 3 December 2024
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 224 (2)
Open AccessOne step 4× and 12× 3D-ExM enables robust super-resolution microscopy of nanoscale cellular structures
Super-resolution microscopy has become an indispensable tool across diverse research fields, offering unprecedented insights into biological architectures with nanometer scale resolution. Compared with traditional nanometer-scale imaging methods such as electron microscopy, super-resolution microscopy offers several advantages, including the simultaneous labeling of multiple target biomolecules with high specificity and simpler sample preparation, making it accessible to most researchers. In this study, we introduce two optimized methods of super-resolution imaging: 4-fold and 12-fold 3D-isotropic and preserved Expansion Microscopy (4× and 12× 3D-ExM). 3D-ExM is a straightforward expansion microscopy technique featuring a single-step process, providing robust and reproducible 3D isotropic expansion for both 2D and 3D cell culture models. With standard confocal microscopy, 12× 3D-ExM achieves a lateral resolution of <30 nm, enabling the visualization of nanoscale structures, including chromosomes, kinetochores, nuclear pore complexes, and Epstein–Barr virus particles. These results demonstrate that 3D-ExM provides cost-effective and user-friendly super-resolution microscopy, making it highly suitable for a wide range of cell biology research, including studies on cellular and chromatin architectures.
- Open Access
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
PET/CT imaging of FAP in vivo. A, Representative PET/CT images of mice bearing subcutaneous 22Rv1/hPrCSC-44 xenografts (white arrowhead). Mice (n = 3/group) received 3.5 MBq (25–50 µg, 7.7 µg/MBq) of [89Zr]Zr-HuB12, 3.6 MBq (25–50 µg, 7.5 µg/MBq) [89Zr]Zr-F19 or 3.4 MBq (25–50 µg, 7.9 µg/MBq) [89Zr]Zr-J591 via tail vein and were imaged at the indicated timepoints. B, Quantitative analysis of subcutaneous xenografts from mice (n = 3/group) revealed significantly higher [89Zr] uptake in the tumors of [89Zr]Zr-HuB12 administered animals compared with the [89Zr]Zr-F19 or [89Zr]Zr-J591 at all timepoints postinjection. Values represent mean ± SEM. *, P ≤ 0.05; **, P ≤ 0.01; ****, P ≤ 0.0001. C, Radio-competition cell binding results using [89Zr]Zr-HuB12 and either the FAP-positive hPrCSC-44 or FAP-negative 22Rv1 cell line. The IC50 was only determinable for hPrCSC-44 and was measured at 11.6 nmol/L.
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
PET/CT imaging of FAP in vivo. A, Representative PET/CT images of mice bearing subcutaneous 22Rv1/hPrCSC-44 xenografts (white arrowhead). Mice (n = 3/group) received 3.5 MBq (25–50 µg, 7.7 µg/MBq) of [89Zr]Zr-HuB12, 3.6 MBq (25–50 µg, 7.5 µg/MBq) [89Zr]Zr-F19 or 3.4 MBq (25–50 µg, 7.9 µg/MBq) [89Zr]Zr-J591 via tail vein and were imaged at the indicated timepoints. B, Quantitative analysis of subcutaneous xenografts from mice (n = 3/group) revealed significantly higher [89Zr] uptake in the tumors of [89Zr]Zr-HuB12 administered animals compared with the [89Zr]Zr-F19 or [89Zr]Zr-J591 at all timepoints postinjection. Values represent mean ± SEM. *, P ≤ 0.05; **, P ≤ 0.01; ****, P ≤ 0.0001. C, Radio-competition cell binding results using [89Zr]Zr-HuB12 and either the FAP-positive hPrCSC-44 or FAP-negative 22Rv1 cell line. The IC50 was only determinable for hPrCSC-44 and was measured at 11.6 nmol/L.
- Open Access
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Proliferation and survival marker gene expression
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Proliferation and survival marker gene expression
- Open Access
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Determining the therapeutic window in the Stacks
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Determining the therapeutic window in the Stacks
- Open Access
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
ADC efficacy in multiple cell lines
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
ADC efficacy in multiple cell lines
- Open Access
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Determining the therapeutic window in the Stacks
- 12 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
Determining the therapeutic window in the Stacks